A panel of outside advisers to the U.S. Food and Drug Administration (FDA) voted to endorse a vaccine from Pfizer for respiratory syncytial virus (RSV) on Tuesday. The majority vote to endorse Pfizer’s product brings it closer to potentially becoming the first approved vaccine for RSV for older adults in the United States. The FDA had…